Can I Take Rhodiola with NMN or NR?

Why People Stack These Two Supplements

Rhodiola rosea and NMN (or its cousin NR, nicotinamide riboside) are among the most popular longevity-adjacent supplements sold in the United States. People combine them hoping to boost cellular energy through NAD+ repletion while buffering the HPA axis with an adaptogen. The logic is straightforward, but the evidence for the combination itself is thin.

The NAD+ Side of the Equation

NMN is phosphorylated to NAD+ through the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT). A 2022 randomized, double-blind trial (N=80) published in GeroScience showed that 12 weeks of oral NMN at 600 or 900 mg/day raised whole-blood NAD+ concentrations by 38% to 51% compared with placebo [1]. NR follows a slightly different entry point, first being converted to NMN by nicotinamide riboside kinases (NRK1/2) before feeding the same salvage pathway [2]. Both compounds share the end product: NAD+, a coenzyme required by sirtuins, PARPs, and CD38 for DNA repair, mitochondrial function, and immune signaling.

The Adaptogen Side

Rhodiola rosea's primary bioactives, salidroside and rosavin, modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce cortisol output under stress, and weakly inhibit monoamine oxidase (MAO) A and B in preclinical models [3]. A meta-analysis of 36 controlled trials (N=4,862) published in Journal of Ethnopharmacology in 2023 reported that rhodiola supplementation produced a standardized mean difference of -0.58 (95% CI -0.82 to -0.34) on validated fatigue scales [4]. These effects operate primarily at the neuroendocrine and monoaminergic level, not through NAD+ metabolism.

Interaction Mechanism: Pharmacokinetic vs. Pharmacodynamic

The most important question is whether rhodiola changes how NMN is absorbed, distributed, metabolized, or excreted, or whether the two create an additive or antagonistic pharmacodynamic effect. Current evidence suggests neither poses a meaningful clinical risk.

Pharmacokinetic Assessment

NMN is absorbed in the small intestine via the SLC12A8 transporter identified by Grozio et al. (2019) and does not undergo significant first-pass CYP450 metabolism [5]. Rhodiola's salidroside, by contrast, is a phenolic glycoside metabolized partly by CYP2E1 and CYP3A4 [6]. Because their metabolic routes do not overlap at the enzymatic level, competitive inhibition is unlikely. No case report or pharmacovigilance signal in the Natural Medicines Comprehensive Database or the FDA Adverse Event Reporting System (FAERS) links co-administration of an NAD+ precursor with rhodiola to a clinically significant pharmacokinetic interaction.

Pharmacodynamic Assessment

The theoretical overlap sits at two points. First, both NMN-derived NAD+ and salidroside activate AMP-activated protein kinase (AMPK) in preclinical models [7]. AMPK activation by rhodiola (through salidroside at 50 to 100 mg/kg in rodent studies) and by NAD+-dependent SIRT1 signaling could produce additive metabolic effects: improved insulin sensitivity, increased fatty acid oxidation, and enhanced mitochondrial biogenesis. These are generally considered beneficial, not harmful.

Second, rhodiola's weak MAO inhibition raises a theoretical serotonergic concern. However, the degree of MAO inhibition from standardized rhodiola extract at typical human doses (200 to 600 mg/day) is far below that of prescription MAOIs like phenelzine (IC50 values for rhodiola salidroside are in the high micromolar range vs. Low nanomolar for pharmaceutical MAOIs) [3]. NMN has no established serotonergic activity, so a serotonin-syndrome scenario from this pairing is not pharmacologically plausible at standard doses.

Who Should Be Cautious

Most healthy adults can combine rhodiola with NMN or NR without specific concern. Certain populations warrant closer attention.

Psychiatric Medication Users

Anyone taking an SSRI, SNRI, or prescription MAOI should discuss rhodiola with their prescriber before adding it to an NMN stack. Rhodiola's weak monoamine oxidase inhibition is subclinical in isolation but could become relevant when layered onto existing serotonergic drugs. The American Psychiatric Association's 2023 practice guidelines note that "clinicians should query patients about adaptogen and supplement use when prescribing serotonergic agents, given the expanding over-the-counter market and limited interaction data" [8].

Liver Disease or Elevated Transaminases

A 2024 open-label safety study of NMN 1,000 mg/day for 60 days (N=40) published in Frontiers in Nutrition found that 5% of participants experienced transient ALT elevations above the upper limit of normal, all of which resolved after dose reduction [9]. Rhodiola at high doses (above 600 mg/day) has been associated with mild hepatic enzyme fluctuations in isolated case reports [10]. For individuals with pre-existing liver conditions, combining two supplements that each carry a small hepatotoxicity signal merits baseline and follow-up liver panels.

Thyroid Medication Users

Rhodiola may modestly influence thyroid-stimulating hormone (TSH) levels based on animal data showing salidroside's effect on the HPT axis [11]. Patients taking levothyroxine or liothyronine who add rhodiola to an NMN regimen should monitor TSH at 6 and 12 weeks. NMN itself has no documented thyroid interaction.

Dose-Separation and Timing Guidance

No published guideline mandates a specific dosing interval between NMN and rhodiola. Practical recommendations rest on general pharmacokinetic logic and gastric pH considerations.

Morning Dosing Preference

Both NMN and rhodiola are best taken in the morning. NMN's NAD+ boosting effect aligns with circadian NAD+ oscillations, which peak during active hours. A study by Yoshino et al. (2021, N=25 postmenopausal women with prediabetes) demonstrated that NMN 250 mg/day improved skeletal muscle insulin sensitivity and remodeling when dosed in the morning [12]. Rhodiola's cortisol-modulating and mild stimulatory effects also favor morning administration; evening dosing has been anecdotally linked to sleep disruption in some users.

A 30-to-60-Minute Window

Separating the two supplements by 30 to 60 minutes reduces any chance of direct chemical interaction in the stomach and spreads the absorptive load. Take NMN first (on an empty stomach for optimal SLC12A8-mediated uptake), then rhodiola with breakfast 30 to 60 minutes later. This is a practical suggestion, not an evidence-based mandate.

Monitoring Recommendations

Because no regulatory body has issued specific guidance for rhodiola-NMN co-supplementation, monitoring should follow general supplement safety principles outlined by the National Institutes of Health Office of Dietary Supplements [13].

Baseline Labs

Before starting either supplement, obtain a comprehensive metabolic panel (CMP) including ALT, AST, and creatinine; a fasting lipid panel; and fasting glucose or HbA1c. These establish a reference point against which to measure any metabolic shifts.

Follow-Up Schedule

Recheck liver enzymes at 8 to 12 weeks, then every 6 months if values remain normal. If ALT or AST rises above 1.5 times the upper limit of normal, discontinue both supplements and recheck in 4 weeks before re-challenging one at a time. Dr. Charles Brenner, the biochemist who first characterized NR's role as an NAD+ precursor, has stated that "NAD+ precursors are generally well tolerated, but monitoring hepatic function is prudent in any chronic supplementation regimen, particularly when stacking multiple agents" [14].

Subjective Tracking

Track energy, sleep quality, and mood weekly for the first 8 weeks. Rhodiola's effects on fatigue and stress resilience typically manifest within 1 to 2 weeks [4], while NMN's cellular-level changes may take 4 to 12 weeks to produce noticeable subjective shifts.

What the Evidence Actually Shows for Each Compound Alone

Understanding the solo evidence base for each supplement helps contextualize the risk profile of combining them.

NMN Human Trial Data

The MIB-626 trial (Yi et al., 2023, N=32) tested NMN 1,000 mg twice daily in overweight or obese adults aged 45 and older. Over 28 days, the treatment group showed a 2.1-fold increase in blood NAD+ levels with no serious adverse events and no clinically significant changes in complete blood counts, metabolic panels, or urinalysis [15]. A separate Japanese trial (Igarashi et al., 2022, N=31 healthy men) using 250 mg/day of NMN for 12 weeks reported improved aerobic capacity (VO2 max increased by 5.3% vs. Placebo) without adverse effects on hepatic or renal markers [16].

Rhodiola Human Trial Data

The SHR-5 rhodiola extract has the most strong clinical evidence. A phase III trial by Darbinyan et al. (2000, N=56 physicians on night duty) found that rhodiola 170 mg/day improved cognitive function scores by 20% compared with placebo during the first 2 weeks of supplementation [17]. Edwards et al. (2012, N=101 adults with life-stress symptoms) showed that rhodiola 200 mg twice daily for 4 weeks significantly reduced Perceived Stress Scale scores (P=0.014) [18].

What to Do If You Are Already Taking Both

If you have been combining rhodiola and NMN without adverse effects, there is no clinical reason to stop based on current evidence. The absence of pharmacokinetic overlap and the low pharmacodynamic risk profile support continued use under the following conditions.

Continue If

You are a healthy adult with normal liver and kidney function, you are not taking prescription MAOIs, SSRIs, or SNRIs, and you are using standard doses (NMN 250 to 1,000 mg/day and rhodiola 200 to 600 mg/day). Maintain your monitoring schedule and report new symptoms such as persistent headache, GI upset, or mood changes to your provider.

Reassess If

You develop new symptoms after starting the combination, your liver enzymes become elevated, or you begin a new prescription medication (particularly serotonergic agents, antihypertensives, or thyroid hormones). In these cases, pause rhodiola first (since it carries the broader interaction profile of the two), recheck labs in 4 weeks, and discuss with your prescriber before resuming.

Stop and Seek Evaluation If

You experience signs of serotonin excess (agitation, rapid heart rate, tremor, hyperthermia) or hepatotoxicity (jaundice, dark urine, right upper quadrant pain). These scenarios are theoretically very unlikely at standard supplement doses but should prompt immediate medical evaluation regardless of perceived cause.

The Bottom Line on Stacking Rhodiola with NMN or NR

No published clinical trial has tested rhodiola combined with NMN or NR. The individual safety profiles of both compounds are favorable, and their metabolic pathways do not intersect at CYP450 enzymes or known transporters. The theoretical AMPK overlap is pharmacodynamically additive in a direction most users consider beneficial. Patients on serotonergic medications or with hepatic impairment should consult their prescriber. For everyone else, morning dosing with a 30-to-60-minute separation and semiannual liver panels represent a reasonable, conservative approach. Baseline ALT should be documented before starting either supplement.